Behavioral effects of a synthetic corticotropin 4-9 analog in patients with depression and patients with Alzheimer's disease.
|
| Abstract |
In an acute trial, three different dosages (60, 300, and 600 micrograms) of the endocrinologically inert but behaviorally active corticotropin 4-9 (ACTH4-9) fragment ebiratide were given to three patients with clinically probable Alzheimer's disease and five patients with a major depressive episode who were psychomotorly retarded. The drug was given intravenously in a double-blind, placebo-controlled, crossover design, and cognitive as well as psychopathologic assessments were carried out predrug and postdrug treatment. In summary, no adverse effect of the ACTH fragment was detected. In this explorative study, none of the patients improved cognitively, as measured by neuropsychologic testing. However, all patients, regardless of underlying disorder, reported a decrease of the feeling of tiredness or loss of energy, respectively. They felt more vigorous and alert. This occurred after any of the three doses of ACTH4-9, but not after placebo. In concert with reports from other studies, it is concluded that the ACTH4-9 fragment ebiratide may have activating properties in humans. However, given acutely, it does not seem to have antidementia or antidepressive efficacy.
|
|---|---|
| Authors | I Heuser, M Heuser-Link, U Gotthardt, A Grasser, F Holsboer |
| Journal | Journal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 13 Issue 3 Pg. 171-4 (Jun 1993) ISSN: 0271-0749 [Print] United States |
| PMID | 8394847 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!